



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 47506(47843)

#10

Patent application of

MARCHIONNI, MARK et al.

Serial No. 09/756,481

Filed: January 8, 2001

For: METHODS FOR TREATING NEUROLOGICAL INJURIES AND DISORDERS

STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:


1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 09/756,481

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,


August 8, 2000  
Date

  
\_\_\_\_\_  
James A. Coburn

**HARBOR CONSULTING**  
Intellectual Property Services  
1500A Lafayette Road  
Suite 262  
Portsmouth, N.H.  
800-318-3021

0300

57



Practitioner's Docket No. 47506 (71095)

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re application of: M. Marchionni et al.  
Application No.: 09/756,481                      GROUP: 1614  
Filed: January 18, 2001                      EXAMINER: Not Yet Assigned  
For: METHODS FOR TREATING NEUROLOGICAL INJURIES AND DISORDERS

Assistant Commissioner for Patents  
Washington, D.C. 20231  
BOX: PCT

**SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,  
AND/OR AMENDMENT PERTAINING THERETO  
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE  
AND/OR AMINO ACID SEQUENCE**

*(check and complete this item, if applicable)*

1. ☒ This replies to the Office Letter DATED July 3, 2002.

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the application number from the return post card or the attorney's docket number added.

☒ A copy of the Office Letter is enclosed.

**IDENTIFICATION OF PERSON MAKING STATEMENT**

2. I, Christine C. O'Day  
*(type or print name of person signing below)*

**CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))**

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**  
  
☒ deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

**FACSIMILE**  
  
☐ transmitted by facsimile to the Patent and Trademark Office.

Date: 8/27/02

Susan M Dillon  
Signature  
Susan M. Dillon  
*(type or print name of person certifying)*

state the following:

### ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

*(check each item as applicable)*

- A. ☒ "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B. ☐ An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. ☒ A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. ☐ Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:

Application No.: 0 /

Filed:

For:

Group No.:

Examiner:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form

(other application)

"Sequence Identifier"

(this application)

*NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. Section 1.821(e).*

- E. ☒ A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. Section 1.821(g).

☐ Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).

F. ☒ Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.

☐ Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

**STATEMENT THAT "SEQUENCE LISTING"  
AND COMPUTER READABLE COPY ARE THE SAME  
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

*(complete applicable item A and/or B)*

A. ☒ Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.

B. ☒ All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

**STATUS**

5. Applicant is

☒ a small entity.

☐ other than a small entity.

**EXTENSION OF TERM**

6.

*NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.*

*If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).*

*NOTE: See 37 C.F.R. Section 1.645 for extensions of time in interference proceedings and 37 C.F.R. Section 1.550(c) for extensions of time in reexamination proceedings.*

7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.

*(complete (a) or (b) as applicable)*

(a) ☐ Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

Extension (months)	Fee for other than small entity	Fee for small entity
[ ] one month	\$ 110.00	\$ 55.00
[ ] two months	\$ 400.00	\$ 200.00
[ ] three months	\$ 920.00	\$ 460.00
[ ] four months	\$1,440.00	\$ 720.00

Fee \$ \_\_\_\_\_

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

- [ ] An extension for \_\_\_\_\_ months has already been secured, and the fee paid therefor of \$ \_\_\_\_\_ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$ \_\_\_\_\_

OR

- (b) [X] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

#### FEE PAYMENT

8. [ ] Attached is a check in the sum of \$ \_\_\_\_\_.
- [ ] Charge Account No. \_\_\_\_\_ the sum of \$ \_\_\_\_\_.
- A duplicate of this transmittal is attached.

#### FEE DEFICIENCY

9.

*NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.*

10. [X] If any additional extension and/or fee is required, charge Account No. 04-1105.

SIGNATURE(s)

(type or print name of person signing statement)

Christ C. M.

8-27-02

Boston, MA 02209


Customer No.: 21874

- ☐ Inventor  
☐ Assignee of complete interest  
☐ Person authorized to sign on behalf of assignee  
☒ Practitioner of record  
☐ Filed under Rule 34(a)  
☐ Registration No.  
☐ Other

(complete the following, if applicable)

Title of person authorized to sign on behalf of assignee

Reel \_\_\_\_\_ Frame \_\_\_\_\_




## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov


APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/756,481	01/08/2001	Mark Marchionni	47506 (71095)

Dike, Bronstein, Roberts & Cushman  
Intellectual Property Practice Group  
Edwards & Angell, LLP  
P.O. Box 9169  
Boston, MA 02209



CONFIRMATION NO. 4213

FORMALITIES LETTER



Date Mailed: 07/03/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin2help@uspto.gov or patin3help@uspto.gov

A copy of this notice **MUST** be returned with the reply.

  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

*Sequence Listing*  
Edwards & Angell LLP  
Dike, Bronstein, Roberts & Cushman  
101 Federal St. Boston, MA 02110  
Date Rec'd 7/8/02  
Docketed For Sep. 3, 2002 - Jan. 3, 2002  
By KRD  
Approved m 7/5/02





## Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 09756481A
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOI		
1 _____ Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."	
2 _____ Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.	
3 _____ Misaligned Amino Numbering	The numbering under each 5 <sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.	
4 _____ Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.	
5 _____ Variable Length	Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.	
6 _____ PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
7 _____ Skipped Sequences (OLD RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped  Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.	
8 _____ Skipped Sequences (NEW RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000	
9 _____ Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
10 _____ Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence	
11 _____ Use of <220>	Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)	
12 _____ PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	
13 _____ Misuse of n	n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.	

AMC/MH - Biotechnology Systems Branch - 08/21/2001

The type of errors shown exist throughout the Sequence Listing. Please check subsequent sequences for similar errors.



OIPE

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/756,481A

DATE: 10/02/2001  
TIME: 11:48:10

Input Set : A:\47506-sequence.txt  
Output Set: N:\CRF3\10022001\I756481A.raw

3 <110> APPLICANT: Mark Marchionni  
4 Michael Jarpe  
5 Ted Ebendal  
7 <120> TITLE OF INVENTION: METHODS FOR TREATING NEUROLOGICAL  
8 INJURIES AND DISORDERS  
10 <130> FILE REFERENCE: 47506 (71095)  
12 <140> CURRENT APPLICATION NUMBER: 09/756,481A  
C--> 13 <141> CURRENT FILING DATE: 2001-08-30  
15 <150> PRIOR APPLICATION NUMBER: PCT/US99/15106  
16 <151> PRIOR FILING DATE: 1999-07-02  
18 <150> PRIOR APPLICATION NUMBER: 60/091,791  
19 <151> PRIOR FILING DATE: 1998-07-06  
21 <160> NUMBER OF SEQ ID NOS: 2  
23 <170> SOFTWARE: FastSEQ for Windows Version 3.0  
25 <210> SEQ ID NO: 1  
26 <211> LENGTH: 1387  
27 <212> TYPE: DNA  
28 <213> ORGANISM: Artificial Sequence  
30 <220> FEATURE:  
31 <221> NAME/KEY: CDS  
32 <222> LOCATION: (218)...(1288)  
W--> 34 <223> OTHER INFORMATION: *Errored*  
34 <400> SEQUENCE: 1  
35 cccttctcca gggactctgg ctgccagcag ctccgccttt cagatcaatt ctogaccacc 60  
36 caccttgga ctgccgcca gtccctgacct ctggatcagt ggggtccaga cagcccccct 120  
37 ccaggacctc aaagcacccc cgacctaaagg tcaccagccc actggcccca gacgcagtgg 180  
38 gtcctcgctga ctctcttggg cacctcctgg gaggaat atg ctc cct gtc tgc cat 235  
39 Met Leu Pro Val Cys His  
40 1 5  
42 cgt ttt tgc gac cac ctc ctc ctc ctg ctc ttg ctg ccc tgc acg acc 283  
43 Arg Phe Cys Asp His Leu Leu Leu Leu Leu Leu Pro Ser Thr Thr  
44 10 15 20  
46 ctg gcc ccc gcg cca gca tcc atg ggc ccc gct gcc gcc ctg ctc cag 331  
47 Leu Ala Pro Ala Pro Ala Ser Met Gly Pro Ala Ala Ala Leu Leu Gln  
48 25 30 35  
50 gtt ctt ggg ctt ccc gaa gcg ccc cgg agc gtc ccc aca cac cga cct 379  
51 Val Leu Gly Leu Pro Glu Ala Pro Arg Ser Val Pro Thr His Arg Pro  
52 40 45 50  
53 gtg cct cct gtc atg tgg cgc cta ttc cgt cgc cgt gac ccc cag gag 427  
54 Val Pro Pro Val Met Trp Arg Leu Phe Arg Arg Arg Asp Pro Gln Glu  
55 55 60 65 70  
57 gcc aga gtg gga cgc cct ctg cgg cca tgc cac gtg gag gaa cta ggg 475  
58 Ala Arg Val Gly Arg Pro Leu Arg Pro Cys His Val Glu Glu Leu Gly  
59 75 80 85  
61 gtc gcc gga aac att gtg cgc cac atc ccc gac agc ggt ctg tcc tcc 523  
62 Val Ala Gly Asn Ile Val Arg His Ile Pro Asp Ser Gly Leu Ser Ser  
63 90 95 100

Does Not Comply  
Corrected Diskette Needed

*A 213 response of 'Artificial Sequence'  
requires an explanation or description  
in field 223*

The type of errors shown exist throughout  
the Sequence Listing. Please check subsequent  
sequences for similar errors.

## RAW SEQUENCE LISTING

DATE: 10/02/2001

PATENT APPLICATION: US/09/756,481A

TIME: 11:48:10

Input Set : A:\47506-sequence.txt

Output Set: N:\CRF3\10022001\I756481A.raw

65	agg ccc gca caa ccc gcc agg acc tcg ggg ctg tgc ccc gag tgg aca	571
66	Arg Pro Ala Gln Pro Ala Arg Thr Ser Gly Leu Cys Pro Glu Trp Thr	
67	105 110 115	
69	gtc gtc ttt gac ctg tcg aat gtg gag ccc aca gag cgc cca aca cgc	619
70	Val Val Phe Asp Leu Ser Asn Val Glu Pro Thr Glu Arg Pro Thr Arg	
71	120 125 130	
73	gcg cgc tta gag ttg cgg ctg gag gct gag tgt gaa gat aca gga ggg	667
74	Ala Arg Leu Glu Leu Arg Leu Glu Ala Glu Cys Glu Asp Thr Gly Gly	
75	135 140 145 150	
77	tgg gag cta agc gtg gca ctg tgg gcc gac gca gag cat cca ggg cct	715
78	Trp Glu Leu Ser Val Ala Leu Trp Ala Asp Ala Glu His Pro Gly Pro	
79	155 160 165	
81	gag ctg ctg cgc gtg ccg gcg cca cca ggg gtg ctc ctg cgc gca gac	763
82	Glu Leu Leu Arg Val Pro Ala Pro Pro Gly Val Leu Leu Arg Ala Asp	
83	170 175 180	
85	cta ctg ggg act gca gta gcc gcc aac gca tca gtg ccc tgt act gtg	811
86	Leu Leu Gly Thr Ala Val Ala Ala Asn Ala Ser Val Pro Cys Thr Val	
87	185 190 195	
89	cgc ctg gcg ctg tca ctg cac cct ggg gcc act gca gcc tgt ggg cgc	859
90	Arg Leu Ala Leu Ser Leu His Pro Gly Ala Thr Ala Ala Cys Gly Arg	
91	200 205 210	
93	ctg gct gag gcc tcc ctg ctg ctg gtg acg ctg gac cca cgc ctg tgt	907
94	Leu Ala Glu Ala Ser Leu Leu Leu Val Thr Leu Asp Pro Arg Leu Cys	
95	215 220 225 230	
97	ccc ttg ccg cga ttg cgg cgc cac acg gag ccc agg gta gaa gtt ggt	955
98	Pro Leu Pro Arg Leu Arg Arg His Thr Glu Pro Arg Val Glu Val Gly	
99	235 240 245	
101	cca gtg ggc act tgt cgt acc cga cgg ttg cat gtg agc ttc cgt gag	1003
102	Pro Val Gly Thr Cys Arg Thr Arg Arg Leu His Val Ser Phe Arg Glu	
103	250 255 260	
105	gtg ggc tgg cac cgt tgg gtg atc gcg ccg cgt ggc ttc cta gcc aac	1051
106	Val Gly Trp His Arg Trp Val Ile Ala Pro Arg Gly Phe Leu Ala Asn	
107	265 270 275	
109	ttc tgc cag ggc acg tgc gca cta ccc gaa acg ctg agg gga ccc ggc	1099
110	Phe Cys Gln Gly Thr Cys Ala Leu Pro Glu Thr Leu Arg Gly Pro Gly	
111	280 285 290	
113	ggg ccg cct gca ctc aac cac gct gtg ctg cgc gcg ctc atg cac gca	1147
114	Gly Pro Pro Ala Leu Asn His Ala Val Leu Arg Ala Leu Met His Ala	
115	295 300 305 310	
117	gct gct ccc acc ccg ggt gca ggc tcg ccc tgc tgc gtg cca gag cgt	1195
118	Ala Ala Pro Thr Pro Gly Ala Gly Ser Pro Cys Cys Val Pro Glu Arg	
119	315 320 325	
121	cta tca ccc atc tcc gtg ctc ttc ttc gac aat agt gac aac gtg gtc	1243
122	Leu Ser Pro Ile Ser Val Leu Phe Phe Asp Asn Ser Asp Asn Val Val	
123	330 335 340	
125	ctg cga cac tac gaa gac atg gtg gtg gat gag tgt ggc tgc cgt	1288
126	Leu Arg His Tyr Glu Asp Met Val Val Asp Glu Cys Gly Cys Arg	
127	345 350 355	
129	tgaccaccg ggacaccctt tcagggaccg cccacgcaa aagcaggac tgtttgttca	1348

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/756,481A

DATE: 10/02/2001

TIME: 11:48:10

Input Set : A:\47506-sequence.txt

Output Set: N:\CRF3\10022001\I756481A.raw

130 tgtttttattg gtgacaaaaa gcttaaaaca aatttgact 1387

132 <210> SEQ ID NO: 2

133 <211> LENGTH: 357

134 <212> TYPE: PRT

135 <213> ORGANISM: Artificial Sequence

W--> 137 <220> FEATURE:

W--> 137 <223> OTHER INFORMATION:

137 <400> SEQUENCE: 2

138	Met	Leu	Pro	Val	Cys	His	Arg	Phe	Cys	Asp	His	Leu	Leu	Leu	Leu	Leu	
139	1				5					10						15	
140	Leu	Leu	Pro	Ser	Thr	Thr	Leu	Ala	Pro	Ala	Pro	Ala	Ser	Met	Gly	Pro	
141				20					25					30			
142	Ala	Ala	Ala	Leu	Leu	Gln	Val	Leu	Gly	Leu	Pro	Glu	Ala	Pro	Arg	Ser	
143				35				40					45				
144	Val	Pro	Thr	His	Arg	Pro	Val	Pro	Pro	Val	Met	Trp	Arg	Leu	Phe	Arg	
145		50					55				60						
146	Arg	Arg	Asp	Pro	Gln	Glu	Ala	Arg	Val	Gly	Arg	Pro	Leu	Arg	Pro	Cys	
147	65					70				75					80		
148	His	Val	Glu	Glu	Leu	Gly	Val	Ala	Gly	Asn	Ile	Val	Arg	His	Ile	Pro	
149				85						90					95		
150	Asp	Ser	Gly	Leu	Ser	Ser	Arg	Pro	Ala	Gln	Pro	Ala	Arg	Thr	Ser	Gly	
151				100					105					110			
152	Leu	Cys	Pro	Glu	Trp	Thr	Val	Val	Phe	Asp	Leu	Ser	Asn	Val	Glu	Pro	
153				115					120					125			
154	Thr	Glu	Arg	Pro	Thr	Arg	Ala	Arg	Leu	Glu	Leu	Arg	Leu	Glu	Ala	Glu	
155		130					135					140					
157	Cys	Glu	Asp	Thr	Gly	Gly	Trp	Glu	Leu	Ser	Val	Ala	Leu	Trp	Ala	Asp	
158	145					150					155				160		
159	Ala	Glu	His	Pro	Gly	Pro	Glu	Leu	Leu	Arg	Val	Pro	Ala	Pro	Pro	Gly	
160					165					170					175		
161	Val	Leu	Leu	Arg	Ala	Asp	Leu	Leu	Gly	Thr	Ala	Val	Ala	Ala	Asn	Ala	
162				180					185					190			
163	Ser	Val	Pro	Cys	Thr	Val	Arg	Leu	Ala	Leu	Ser	Leu	His	Pro	Gly	Ala	
164				195					200					205			
165	Thr	Ala	Ala	Cys	Gly	Arg	Leu	Ala	Glu	Ala	Ser	Leu	Leu	Leu	Val	Thr	
166		210					215					220					
167	Leu	Asp	Pro	Arg	Leu	Cys	Pro	Leu	Pro	Arg	Leu	Arg	Arg	His	Thr	Glu	
168	225				230						235				240		
169	Pro	Arg	Val	Glu	Val	Gly	Pro	Val	Gly	Thr	Cys	Arg	Thr	Arg	Arg	Leu	
170				245						250					255		
171	His	Val	Ser	Phe	Arg	Glu	Val	Gly	Trp	His	Arg	Trp	Val	Ile	Ala	Pro	
172				260					265					270			
173	Arg	Gly	Phe	Leu	Ala	Asn	Phe	Cys	Gln	Gly	Thr	Cys	Ala	Leu	Pro	Glu	
174			275				280						285				
175	Thr	Leu	Arg	Gly	Pro	Gly	Gly	Pro	Pro	Ala	Leu	Asn	His	Ala	Val	Leu	
176		290				295						300					
177	Arg	Ala	Leu	Met	His	Ala	Ala	Ala	Pro	Thr	Pro	Gly	Ala	Gly	Ser	Pro	
178	305				310						315				320		
179	Cys	Cys	Val	Pro	Glu	Arg	Leu	Ser	Pro	Ile	Ser	Val	Leu	Phe	Phe	Asp	

## RAW SEQUENCE LISTING

DATE: 10/02/2001

PATENT APPLICATION: US/09/756,481A

TIME: 11:48:10

Input Set : A:\47506-sequence.txt

Output Set: N:\CRF3\10022001\I756481A.raw

180				325					330					335		
181	Asn	Ser	Asp	Asn	Val	Val	Leu	Arg	His	Tyr	Glu	Asp	Met	Val	Val	Asp
182				340					345					350		
183	Glu	Cys	Gly	Cys	Arg											
184				355												

## VERIFICATION SUMMARY

DATE: 10/02/2001

PATENT APPLICATION: US/09/756,481A

TIME: 11:48:11

Input Set : A:\47506-sequence.txt

Output Set: N:\CRF3\10022001\I756481A.raw

L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:34 M:258 W: Mandatory Feature missing, &lt;223&gt; OTHER INFORMATION:

L:137 M:258 W: Mandatory Feature missing, &lt;220&gt; FEATURE:

L:137 M:258 W: Mandatory Feature missing, &lt;223&gt; OTHER INFORMATION:

## STATISTICS SUMMARY

PATENT APPLICATION: US/09/756,481A

DATE: 10/02/2001

TIME: 11:48:11

Input Set : A:\47506-sequence.txt

Output Set: N:\CRF3\10022001\I756481A.raw

Application Serial Number: US/09/756,481A

Alpha or Numeric: Numeric

Application Class:

Application File Date: 08-30-2001

Art Unit: OIPE

Software Application: FastSeq

Total Number of Sequences: 2

Total Nucleotides: 1387

Total Amino Acids: 357

Number of Errors: 0

Number of Warnings: 3

Number of Corrections: 1

## MESSAGE SUMMARY

258 W: 3 (Mandatory Feature missing)

271 C: 1 (Current Filing Date differs)